[A15-56] Pembrolizumab - Addendum to Commission A15-33
Last updated 05.10.2017
Project no.:
A15-56
Commission:
Commission awarded on 22.12.2015 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A15-33 | Pembrolizumab - Benefit assessment according to §35a Social Code Book V (dossier assessment) | Commission completed |
Federal Joint Committee (G-BA)
2016-02-04 A G-BA decision was published.